Participation in the study takes 3 visits over a period of approximately six weeks. The first visit is a screening visit to determine if participants are eligible to participate. After the initial assessment visit, participants will be randomized to one of two groups. Group 1 will have compliance measured by self-report and urine riboflavin levels. This group will not receive computer-chipped capsules, but will receive their medication in a bottle capped with a MEMS Track Cap, which records when the medication bottle is opened and closed. Group 2 will receive computer-chipped capsules and will have compliance measured by self-report, urine riboflavin levels, and data collected by an e-Tect reader. Participants randomized to this group will also receive reminder calls and/or text messages to ingest the study medication if a signal is not sent from the e-Tect reader to the study team within one hour of the scheduled medication administration time. They will also be using biometric identification technology to ensure that they are taking the capsules as directed, specifically electrocardiogram (ECG).